Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 5
Opinion
Video
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Author(s):
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.
Video Player is loading.
Video content above is prompted by the following:
- What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
- Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
- What are your impressions of the BOND-003 data?
Related Videos
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
Navigating Access Barriers: Resources to Support New Treatment Access
Overcoming Challenges in Accessing New Therapies for NMIBC
Selecting Between Receptor Pathway Inhibitors for mHSPC
The Use of Ultra-Low PSA in Specific Patient Profiles
The MOA of TLX250
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
The ZIRCON Trial
Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
Related Content
